A phase 1 study of interleukin-15 in combination with avelumab in relapsed or refractory T-cell lymphoma

Leuk Lymphoma. 2024 Jul;65(7):1008-1011. doi: 10.1080/10428194.2024.2326847. Epub 2024 Mar 9.
No abstract available

Publication types

  • Clinical Trial, Phase I

MeSH terms

  • Adult
  • Aged
  • Antibodies, Monoclonal, Humanized* / administration & dosage
  • Antibodies, Monoclonal, Humanized* / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols* / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
  • Drug Resistance, Neoplasm
  • Female
  • Humans
  • Interleukin-15*
  • Lymphoma, T-Cell* / drug therapy
  • Lymphoma, T-Cell* / pathology
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / drug therapy
  • Neoplasm Recurrence, Local / pathology
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • avelumab
  • Interleukin-15